The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

Chronic pain is the most common complication affecting adults with sickle cell disease (SCD). 1 Pain profoundly affects people’s quality of life, functional ability, and health care utilization.

New Orleans, LA - A randomized, controlled trial found that treatment with an implantable cardioverter defibrillator (ICD) on top of standard medications reduced the hazard ratio for five-year ...

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A growing landscape for sickle cell disease (SCD) treatments, a growing relationship between the companies, and the potential ...

This new economic valuation of the societal and health care benefits of gene therapy to treat sickle cell disease (SCD) concludes the highly personalized treatment has potential to be cost effective ...

SCD is inherited as an autosomal codominant trait 1; individuals who are heterozygous for the β S allele carry the sickle cell trait (HbAS) but do not have SCD, whereas individuals who are homozygous ...

Sickle cell disease (SCD) is a pressing global health issue, with rising cases and mortality, especially in low- and middle-income countries (LMICs). Hydroxyurea, a cost-effective treatment for SCD, ...